Sangamo Therapeutics, Inc.

As of June 30, 2024, Sangamo Therapeutics, Inc. has 208.20M shares outstanding.

These figures are as of June 30, 2024. The EV/Sales ratio of 0.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2024, Sangamo Therapeutics, Inc. maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -119.44, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2024, Sangamo Therapeutics, Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,681.69 and net profit margin of -2,033.68 provide insight into operational efficiency.

As of June 30, 2024, Sangamo Therapeutics, Inc. has an Altman Z-Score of -29.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.